*仅供医学专业人士阅读参考
直击2024 SABCS,紧跟乳腺癌治疗前沿
整理丨医学界报道组
2024年12月10日-13日,第47届圣安东尼奥乳腺癌研讨会(San Antonio Breast Cancer Symposium,SABCS)将在美国得克萨斯州圣安东尼奥举行。
日前,大会公布了摘要标题,医学界特整理LBA Oral Session、General Session、Rapid Fire Session、Poster Spotlight Sessions中HER2阳性乳腺癌相关的口头报告研究,以供读者参考。
LBA Oral Session
摘要号:LB1-02
MARGOT/TBCRC052:A randomized phase II trial comparing neoadjuvant paclitaxel/margetuximab/pertuzumab(TMP)vs paclitaxel/trastuzumab/pertuzumab(THP)in patients(pts)with stage II-III HER2+ breast cancer.
随机II期MARGOT/TBCRC052研究:紫杉醇+马吉妥昔单抗+帕妥珠单抗(TMP方案)vs 紫杉醇+曲妥珠单抗+帕妥珠单抗(THP方案)新辅助治疗II/III期HER2阳性乳腺癌患者的疗效
讲者:Adrienne Waks, Dana-Farber Cancer Institute, Boston, Massachusetts
General Session
摘要号:GS1-03
Pyrotinib or placebo in combination with trastuzumab and docetaxel for untreated HER2-positive metastatic breast cancer (mBC):prespecified final analysis of progression-free survival (PFS) of the phase 3 PHILA trial.
III期PHILA研究的无进展生存期(PFS)预设最终分析:吡咯替尼/安慰剂联合曲妥珠单抗和多西他赛治疗未经治的HER2阳性转移性乳腺癌(mBC)
讲者:徐兵河 中国医学科学院肿瘤医院
摘要号:GS1-04
HER2-Directed Antibody-Drug Conjugate SHR-A1811 in the Neoadjuvant Treatment of HER2-positive Early Breast Cancer:a Prospective, Randomized, Open-label, Phase 2 Trial.
SHR-A1811(靶向HER2抗体偶联药物)新辅助治疗HER2阳性早期乳腺癌:一项前瞻性、随机、开放标签、II期研究
讲者:李俊杰 复旦大学附属肿瘤医院
摘要号:GS3-01
Circulating tumor DNA surveillance in ZEST, a randomized, phase 3, double-blind study of niraparib or placebo in patients with triple-negative breast cancer or HER2+ BRCA-mutated breast cancer with molecular residual disease after definitive therapy.
随机、双盲、III期ZEST研究中的循环肿瘤DNA监测分析:评估尼拉帕利或安慰剂用于根治性治疗后仍存在残留病灶的三阴性乳腺癌或HER2阳性伴有BRCA突变乳腺癌患者
讲者:Nicholas Turner, Ralph Lauren Centre for Breast Cancer Research, London, United Kingdom
Rapid Fire Session
摘要号:RF1-02
Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR+/HER2+ early breast cancer:primary results from the randomized phase II TOUCH trial (IBCSG 55-17).
哌柏西利+来曲唑vs单周紫杉醇,与曲妥珠单抗和帕妥珠单抗联用新辅助治疗HR+/HER2+早期乳腺癌患者:随机II期TOUCH研究(IBCSG 55-17)的主要结果
讲者:Luca Malorni, USL Toscana Centro, Hospital of Prato, Prato, Italy
摘要号:RF1-03
Three-year event-free survival (EFS) of the multicenter phase II TRAIN-3 study evaluating image-guided optimization of neoadjuvant chemotherapy duration in stage II and III HER2-positive breast cancer (BOOG 2018-01).
多中心、II期TRAIN-3研究的3年无事件生存期(EFS)分析:基于影像引导优化II/III期HER2阳性乳腺癌新辅助化疗持续时间(BOOG 2018-01)
讲者:Fleur Louis, Antoni van Leeuwenhoekziekenhuis, Amsterdam, Netherlands
摘要号:RF1-07
Multifactor analysis for pathologic complete response (pCR) in a chemotherapy-free regimen of durvalumab, trastuzumab, and pertuzumab (DTP Trial) in HER2-enriched early breast cancer.
病理完全缓解率(pCR)的多因素分析:度伐利尤单抗联合曲妥珠单抗和帕妥珠单抗无化疗方案(DTP试验)治疗HER2过表达的早期乳腺癌
讲者:Bojana Stefanovska, UT Health Science Center, San Antonio, Texas
摘要号:RF3-04
NRG-BR004:A Randomized, Double-blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-line HER2-positive Metastatic Breast Cancer.
NRG-BR004试验:一项评估紫杉醇/曲妥珠单抗/帕妥珠单抗联合阿替利珠单抗或安慰剂一线治疗HER2阳性mBC疗效的随机、双盲、III期研究
讲者:Vicente Valero, MD Anderson Cancer Center, Houston, Texas
Poster Spotlight Sessions
摘要号:PS1-03
Prediction of Prognosis and Efficacy of Neoadjuvant Therapy in HER2-Positive Breast Cancer Patients Based on Tertiary Lymphoid Structures.
基于三级淋巴结构预测HER2阳性乳腺癌患者新辅助治疗的疗效和预后
讲者:张克兢 中南大学湘雅医院
摘要号:PS4-06
HER2DX ERBB2 mRNA Score in First-Line Metastatic HER2-Positive Breast Cancer Treated with Docetaxel, Trastuzumab and Pertuzumab:Correlative Analysis from CLEOPATRA Phase III Trial.
HER2DX ERBB2 mRNA评分在多西他赛联合曲妥珠单抗和帕妥珠单抗一线治疗HER2阳性mBC中的应用:III期CLEOPATRA研究的相关分析
讲者:Javier Cortés, Hospital Universitario Ramón y Cajal, Madrid, Spain
摘要号:PS4-08
The tumor heterogeneous overexpressed CD155 promotes treatment resistance in HER2-positive breast cancer through immune microenvironment modulation.
肿瘤异质性过表达CD155通过免疫微环境调节促进HER2阳性乳腺癌治疗耐药性
讲者:张怡 复旦大学附属肿瘤医院
摘要号:PS8-02
A Phase 1 study Evaluating the Safety, Efficacy and Pharmacokinetics of TL938 in HER2-Positive Patients with Advance Solid Tumors.
评估TL938在HER2阳性晚期实体瘤患者中的安全性、有效性和药代动力学的I期研究
讲者:石远凯 中国医学科学院肿瘤医院
摘要号:PS8-03
Exploratory biomarker analysis of Trastuzumab deruxtecan (T-DXd) vs Trastuzumab emtansine (T-DM1) efficacy in human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC) in DESTINY-Breast03 (DB-03).
DESTINY-Breast03(DB-03)研究中的探索性生物标志物分析:德曲妥珠单抗(T-DXd)vs恩美曲妥珠单抗(T-DM1)在HER2阳性mBC中的疗效
讲者:William Jacot, Montpellier Cancer Institute and University of Montpellier, Montpellier, France
摘要号:PS8-05
ACE-Breast-08:a phase I study of ARX788, a novel anti-HER2 antibody-drug conjugate, in patients with TKI pretreated HER2 positive advanced breast cancer.
I期ACE-Breast-08研究:ARX788(一种新型抗HER2 ADC)用于经TKI治疗的HER2阳性晚期乳腺癌患者
讲者:王晓稼 浙江省肿瘤医院
摘要号:PS8-06
A randomized, open-label phase III study comparing disitamab vedotin (an anti-HER2 monoclonal antibody-MMAE conjugate) with lapatinib plus capecitabine in patients with HER2-positive, advanced breast cancer with liver metastasis.
维迪西妥单抗(一种抗HER2单克隆抗体-MMAE偶联物)vs拉帕替尼联合卡培他滨在HER2阳性、晚期乳腺癌伴肝转移患者中的疗效:一项随机、开放标签III期研究
讲者:王佳玉 中国医学科学院肿瘤医院
摘要号:PS8-07
Efficacy and Safety of GQ1005, a Promising HER2-ADC, in Patients with Metastatic HER2-Positive Breast Cancer.
GQ1005(一种有潜力的HER2-ADC)在HER2阳性转移性乳腺癌患者中的疗效和安全性分析
讲者:王碧芸 复旦大学附属肿瘤医院
摘要号:PS8-08
fficacy and safety of SHR-A1811, an anti-HER2 antibody-drug conjugate (ADC), in 391 heavily pretreated multiple solid tumors with HER2-expression or mutations:a global, multi-center, first-in-human, phase 1 study.
SHR-A1811(一种HER2-ADC)在391例经多线治疗的HER2表达或突变的多发性实体瘤中的疗效和安全性:全球多中心首次人体I期研究
讲者:姚和瑞 中山大学孙逸仙纪念医院
摘要号:PS8-09
Zanidatamab in combination with evorpacept in HER2-positive and HER2-low metastatic breast cancer:Results from a phase 1b/2 study.
Zanidatamab联合evorpacept治疗HER2阳性和HER2低表达mBC:Ib/II期研究结果
讲者:Alberto Montero, University Hospitals Cleveland Medical Center, Cleveland, Ohio
摘要号:PS13-07
Enhancing T-DXd Efficacy in HER2-positive Breast Cancer Resistant to HER2 ADC by Non-biased Kinase-related Target Screening.
通过非偏向性的激酶相关靶点筛选,增强T-DXd在HER2 ADC耐药的HER2阳性乳腺癌患者中的疗效
讲者:Jangsoon Lee, University of Hawai’i Cancer Center, Honolulu, Hawaii
摘要号:PS14-10
Effects of trastuzumab deruxtecan (T-DXd) on health-related quality of life (HRQOL) & neurological function in patients (pts) with HER2+ advanced/metastatic breast cancer (mBC) with or without brain metastases (BM):DESTINY-Breast12(DB-12) results
DESTINY-Breast12(DB-12)研究结果:德曲妥珠单抗(T-DXd)对伴或不伴脑转移(BM)HER2阳性晚期/mBC患者的健康相关生活质量(HRQOL)和神经功能的影响
讲者:Nadia Harbeck, Ludwig-Maximilians-Universitӓt München (LMU), Munich, Germany
*研究依据摘要号顺序进行排列,如有任何遗漏,敬请留言!
精彩资讯等你来
责任编辑:Sheep
*医学界力求其发表内容专业、可靠,但不对内容的准确性做出承诺;请相关各方在采用或以此作为决策依据时另行核查。
特别声明:以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布,本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.